8-K: Artelo Biosciences Secures $690K in Convertible Debt

Artelo Biosciences, Inc. has completed a private placement of $690,154.69 in convertible notes and warrants to purchase 438,182 shares, including participation from company directors and officers.

Summary

• Artelo Biosciences, Inc. issued convertible notes (Notes) totaling $690,154.69 in aggregate principal amount and warrants (Warrants) to purchase 438,182 shares of common stock.
• The Notes accrue interest at a rate of 12% per annum, which will adjust to 20% upon an Event of Default.
• All unpaid principal and accrued interest on the Notes are due and payable on April 28, 2026 (the Maturity Date).
• The Notes are convertible, in whole or in part, into shares of common stock at a conversion price of $3.40 per share.
• Each Warrant is immediately exercisable for five years at an exercise price of $3.40 per share.
• This offering was completed by converting a portion of the unpaid principal balance and accrued interest from previously issued convertible promissory notes dated May 1, 2025.
• Company directors and officers participated in the offering, purchasing $158,345.81 in Notes and receiving Warrants for 100,534 shares.
• The Company has agreed to file a registration statement with the SEC on or before the 20th calendar day following the October 28, 2025 closing date, to register the resale of the shares issuable upon conversion of the Notes and exercise of the Warrants.

Sentiment

Score: 6

Explanation: The capital raise addresses immediate financial needs by converting maturing debt, and insider participation is a positive signal. However, the high interest rate on the notes and the potential for significant dilution from both notes and warrants introduce notable risks.

Positives

• Successfully secured financing to address maturing debt obligations and provide capital for operations.
• Participation by company directors and officers (Connie Matsui, Tamara Favorito, Gregory Gorgas) in the offering signals management confidence in the company's future prospects.
• The conversion of prior debt into new convertible notes and warrants provides a structured approach to managing existing financial obligations.

Negatives

• The issuance of convertible notes and warrants will lead to potential dilution for existing shareholders upon conversion or exercise.
• A 12% annual interest rate on the notes, escalating to 20% upon an Event of Default, is relatively high, suggesting a higher risk profile or limited access to lower-cost capital.
• The fact that investors did not voluntarily convert the May 2025 notes into common stock suggests a preference for debt instruments over equity at that time.

Risks

• **Dilution Risk:** Future conversion of the Notes and exercise of the Warrants will increase the number of outstanding common shares, potentially diluting the ownership percentage and earnings per share of current shareholders.
• **Default Risk:** An Event of Default on the Notes would trigger a higher interest rate of 20% per annum, increasing the company's financial burden.
• **Registration Statement Delays:** The company may experience 'Blackout Periods' (up to 90 days per instance, not exceeding 120 days in any twelve-month period) in filing or maintaining the effectiveness of the registration statement for resale of the shares, which could impact investors' ability to sell their shares.
• **Beneficial Ownership Limitations:** Conversion and exercise limits (initially 4.9%, adjustable up to 19.9%) could restrict large investors from fully converting or exercising their holdings immediately.

Future Outlook

The Company is obligated to file a registration statement within 20 calendar days of the closing date to register the resale of shares issuable upon conversion of the notes and exercise of the warrants. The notes have a maturity date of April 28, 2026, and the warrants are exercisable for five years.

Management Comments

• The participation of these Investors in the Offering was disclosed to, and approved by, the board and separately by the disinterested members of the board.

Industry Context

This financing event is typical for a biotechnology company like Artelo Biosciences, which often relies on capital raises to fund research and development, clinical trials, and general corporate purposes. The use of convertible notes and warrants is a common strategy to attract investors while managing immediate cash outflow, though it introduces future dilution potential.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Connie Matsui (Director) purchased a Note with a principal amount of $110,842.52 and Warrants for 70,376 shares.
• Tamara Favorito (Director) purchased a Note with a principal amount of $19,792.93 and Warrants for 12,566 shares.
• Gregory Gorgas (Director and Officer) purchased a Note with a principal amount of $27,710.36 and Warrants for 17,592 shares.

Stakeholder Impact

• **Shareholders:** Potential for dilution from the conversion of notes and exercise of warrants, which could impact per-share metrics.
• **Creditors:** Existing May 2025 noteholders had their debt converted into new convertible notes and warrants, restructuring their investment.
• **Investors (New/Participating):** Received convertible notes with a 12% interest rate and warrants, offering potential upside through equity conversion/exercise.
• **Company:** Secured necessary financing to manage maturing debt and support operations, but incurs new debt obligations and potential future equity dilution.

Next Steps

• File a registration statement with the SEC for the resale of the Converted Shares and Warrant Shares on or before the 20th calendar day following October 28, 2025.
• Use reasonable best efforts to have the registration statement declared effective within 60 days (for S-3) or 90 days (for S-1) of filing, or 45 days if not reviewed by the Commission.
• Keep the registration statement effective until the Registrable Shares can be sold without volume or manner-of-sale restrictions under Rule 144.
• Manage the maturity of the convertible notes on April 28, 2026.
• Address potential warrant exercises over the next five years.

Key Dates

Recommendation

While the financing addresses immediate debt obligations and shows insider confidence, the high interest rate on the convertible notes and the potential for significant dilution from both the notes and warrants warrant caution. Existing investors should hold to observe the company's execution on its strategic plans and how the dilution impacts future share performance. New investors should await further clarity on operational progress and financial stability before making a decision.

Keywords

Artelo Biosciences, ARTL, convertible notes, warrants, private placement, capital raise, SEC filing, 8-K, dilution, corporate finance, Nasdaq, debt financing, equity financing